Good morning, traders and dealmakers. It’s Monday, May 11, and we’ve got a fresh batch of market-moving headlines to kick off the week. Fast, fierce, and zero tolerance for fluff. Let’s dive in.
Market Pulse: Currencies jolted at the Monday open as the New Zealand dollar shrugged off bearish hedge-fund wagers on hawkish signals from the RBNZ, while broader asset classes started mixed in Asia.
Key Movers: Tata Consumer leapt on a better-than-expected quarterly beat flagged by Morgan Stanley, while Titan slid after Prime Minister Modi’s gold-purchase caution rattled jewelers. Crypto traders are eyeing Bitcoin’s funding rates—now at 2020 lows.
Macro & Politics: Modi’s public dig at non-essential gold purchases sent Titan down 8%, a reminder that political sound bites can swing sentiment. Meanwhile, the FDA’s semaglutide ban proposal is looming over biotech supply chains.
What’s Next: All eyes turn to the RBNZ’s next policy meeting and fresh central-bank commentary this week for the next directional catalyst.
📈 Breaking Financial News
Tata Consumer shares soar 7% after better-than-expected Q4 earnings. Here’s what Morgan Stanley & other top brokerages say
Tata Consumer Products shares rose sharply on Monday after strong Q4 earnings beat estimates. Consolidated net profit rose 21% YoY, supported by robust India-branded business performance. Brokerages including Morgan Stanley, Motilal Oswal and Elara Capital revised their outlook higher, citing margin resilience and better pricing power.
Titan shares tumble 8% after PM Modi’s gold purchase remarks overshadow Q4 earnings beat
Titan Company shares fell 8 per cent in early trade on Monday after Prime Minister Narendra Modi urged citizens to avoid non-essential gold purchases for one year to help reduce pressure from forex outflows amid West Asia war, dampening sentiment around jewellery demand despite a Q4 beat.
Morgan Stanley drops one big takeaway in CVS stock earnings beat
Healthcare stocks have had a rough stretch. Rising medical costs, Medicaid pressure, and persistent skepticism about managed care margins have kept investors wary, but CVS delivered a surprising beat and Morgan Stanley highlighted an upside catalyst in pharmacy services.
Bitcoin Funding Rates Fall To 2020 Lows On Binance — Fuel For Further Upside?
After multiple weeks hovering below $80,000, Bitcoin finally broke above the psychological level on Monday, May 4th. The premier cryptocurrency enjoyed a significant surge in bullish momentum, pushing its price to as high as $82,000 over the past week. While funding rates have slumped to depths not seen since 2020, a sentiment shift could trigger a brutal short squeeze.
Kiwi May Defy Hedge-Fund Bears on Hawkish RBNZ, Analysts Say
New Zealand’s dollar may defy bearish hedge-fund positioning and rally in the near-term on a hawkish tilt from the central bank and any de-escalation in the Middle East, analysts say. The RBNZ’s recent minutes suggest officials aren’t done tightening, setting the stage for a surprise move.
Futurist Eric Fry says it will be a “Summer of Surge” for these three stocks
another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. Watch now…
🔍 Market Analysis & Insights
SBI shares crash 10% in two days after Q4. Do Morgan Stanley, Citi, Bernstein and others see upside in Swiggy?
SBI shares fell over 3% on Monday and are down 10% in two sessions despite the lender reporting a 6% YoY rise in Q4 standalone net profit to Rs 19,684 crore. Net interest income rose 4%, while provisions declined sharply. However, softer net interest margins led to analyst skepticism on future growth.
Beyond Nifty: The 10 smallcap stocks that doubled investor wealth in the first 25 sessions of FY27
Indian smallcap stocks are delivering impressive returns early in FY27. Over ten stocks have doubled investor wealth in just 25 sessions. This surge is driven by genuine earnings growth, with many companies exceeding expectations. While the Nifty shows modest gains, these smallcaps are stealing the show.
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced a positive outcome from its final pre-BLA meeting with the FDA and reported its first quarter financial results.
How a pill approved 25 years ago transformed cancer treatment
When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer care.
FDA proposes ban on bulk compounding of semaglutide and tirzepatide
The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, potentially limiting large-scale production by outsourcing facilities. Expect lawsuits, headlines, and a scramble for alternative supply chains.
💰 Investment Opportunities
Alpha Metallurgical Resources Shareholders Approve All Proposals at Annual Meeting
Alpha Metallurgical Resources (NYSE:AMR) held its 2026 annual meeting of stockholders via live webcast, with shareholders approving all three proposals.
Micron stock sends a strong signal amid chip shortage
Micron Technology stock went parabolic last week, rising 15% in a single session on May 8. Over the last five trading sessions, the chip stock has risen sharply amid broad chip supply constraints.
Sleep Apnea Devices Market Expands Rapidly as Awareness, Obesity, and Home Healthcare Drive Demand
Technological innovation, rising diagnosis rates, and the shift toward home-based sleep therapy are transforming the future of sleep apnea treatment worldwide.
Alpha Metallurgical Resources Q1 Earnings Call Highlights
Alpha Metallurgical Resources (NYSE:AMR) reported a modest sequential increase in adjusted EBITDA for the first quarter of 2026, while management said lower operating costs helped offset softer volumes.
Bitcoin holds near $80,000 after rejection at $82,500; ETF outflows trigger cautious sentiment
Bitcoin hovers near the $80,000 mark. Experts note cautious sentiment following outflows from US-listed spot Bitcoin ETFs. Major altcoins like XRP, BNB, and Solana saw gains. The global crypto market capitalization increased. Institutional demand continues to underpin the space.
The Elon Musk “Mystery Metal” That Could Break China's Grip Trump called America's rare-ea
quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.
Enhanced Market Commentary
What everyone’s missing is how the Kiwi dollar’s rally isn’t just a side story. According to Financial Post, “Kiwi May Defy Hedge-Fund Bears on Hawkish RBNZ, Analysts Say,” every short position out there is sitting on a powder keg. If the RBNZ even hints at another hike, those hedge funds will get squeezed hard—and fast.
Connect that to the FDA’s move to ban bulk compounding of semaglutide and tirzepatide (Medical News Today). On the surface, these sound like two separate themes: currency policy and weight-loss drug regulation. But both reflect a bigger truth: regulators will moonwalk on market sentiment when they smell risk. From central banks to pharma overseers, policy risk is a stealthy beast.
Action-oriented takeaway: position for a potential New Zealand dollar squeeze, but hedge with biotech or health-tech names that could rerate once compounding shops scramble. And don’t ignore Bitcoin’s funding metrics—if sentiment flips, we could see a brutal short-covering rally.